Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Charlotte’s Web donates $1-million (US) worth of CBD in memory of Charlotte Figi

Charlotte’s Web (TSX:CWEB; OTC:CWBHF) donated $1-million (US) worth of CBD product to individuals who rely on the company’s products and may be struggling financially as a result of the COVID-19 pandemic. The...

April 21, 2020

Developments

Bee Vectoring gets strong endorsement from Georgia blueberry growers

With Georgia’s blueberry blooming period now complete, growers in the region using Bee Vectoring Technologies’ (TSXV, CVE: BEE; OTCQB:BEVVF) crop protection system reported high fruit set and low fruit drop, both...

April 21, 2020

Developments

Karyopharm Therapeutics doses first COVID-19 patient in selinexor study

Karyopharm Therapeutics (NASDAQ:KPTI) dosed the first patient in a Phase 2 clinical study evaluating low-dose oral selinexor in hospitalized patients with severe COVID-19. Selinexor is designed to block XPO1, a...

April 20, 2020

Developments

CytoSorbents gets FDA breakthrough therapy designation for CytoSorb

The FDA granted breakthrough therapy designation to CytoSorbents‘ (NASDAQ:CTSO) CytoSorb blood purification technology for the removal of ticagrelor during emergency surgery. Ticagrelor is an antiplatelet drug...

April 20, 2020

Developments

Mustang Bio MB-107 gets EMA advanced therapy medicinal product classification

The European Medicines Agency granted Mustang Bio’s (NASDAQ:MBIO) MB-107 with advanced therapy medicinal product classification for the treatment of X-linked severe combined immunodeficiency. Patients with X-linked...

April 20, 2020

Developments

Anixa Biosciences in COVID-19 development pact with OntoChem

Anixa Biosciences (NASDAQ:ANIX) entered a strategic collaboration with OntoChem GmbH to discover and develop anti-viral drug candidates for COVID-19. “We believe that newly designed drugs that are purposefully developed...

April 20, 2020

Markets

HCW starts Bicycle Therapeutics at buy; PT $25

H.C. Wainwright initiated coverage of Bicycle Therapeutics (NASDAQ:BCYC) with a “buy” rating and $25 price target. The stock finished at $14.66 on April 17. The company is focused on bicycles, which are synthetic, short...

April 20, 2020

Markets

Mackie cuts Medicure PT to $2.80 from $6.50

Mackie Research slashed its price target for Medicure (TSXV:MPH) to $2.80 from $6.50, and maintained a “hold” rating, citing highly lowered revenue estimates. The stock closed at $2.41 on April 15. Analyst Andre Uddin...

April 16, 2020

Markets

BTIG ups Arcus Biosciences PT to $34 from $20

BTIG raised its price target for Arcus Biosciences (NYSE:RCUS) to $34 from $20, citing investors meetings with Arcus management that “reinforced careful development of important assets.” The stock closed at $15.58 on...

April 16, 2020

Developments

Vanda Pharma enrolls first patient in Phase 3 COVID-19 trial

Vanda Pharmaceuticals (NASDAQ:VNDA) enrolled the first patient in its Phase 3 trial assessing tradipitant for the treatment of neurogenic inflammation of the lung, secondary to COVID-19 infection. The study will enroll...

April 15, 2020

Developments

FDA approves Urogen Pharma’s urothelial cancer drug

The FDA approved UroGen Pharma’s (NASDAQ:URGN) mitomycin gel for the treatment of low-grade upper tract urothelial cancer (UTUC). The gel, which will be marketed under the brand name Jelmyto, inhibits DNA transcription...

April 15, 2020

Developments

Chembio gets FDA emergency use authorization for serological COVID-19 test

The FDA granted emergency use authorization to Chembio Diagnostics’ (NASDAQ:CEMI) dual path platform (DPP) COVID-19 system. The system is a serological point-of-care test and analyzer that provides numerical readings...

April 15, 2020

Subscribe